| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w28858 |
| 来源ID | Working Paper 28858 |
| Market Size and Research: Evidence from the Pharmaceutical Industry | |
| Dennis Byrski; Fabian Gaessler; Matthew J. Higgins | |
| 发表日期 | 2021-05-31 |
| 出版年 | 2021 |
| 语种 | 英语 |
| 摘要 | Prior literature has established a link between changes in market size and pharmaceutical innovation; whether a link exists with scientific research remains an open question. If upstream research is not responsive to these changes, the kinds of scientific discoveries that flow into future drug development could be disconnected from downstream demand. We explore this question by exploiting the effects of quasi-experimental variation in market size introduced by Medicare Part D. We find no causal relationship between market size and biomedical research in the decade following the implementation of Medicare Part D. While many factors have been shown to motivate scientists to conduct research, this result suggests that changes in market size provide no such incentive. We do find, however, limited support for a response by corporate scientists conducting applied research. Implications for pharmaceutical innovation policy are discussed. |
| 主题 | Health, Education, and Welfare ; Health ; Industrial Organization ; Industry Studies ; Development and Growth ; Innovation and R& ; D |
| URL | https://www.nber.org/papers/w28858 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/586532 |
| 推荐引用方式 GB/T 7714 | Dennis Byrski,Fabian Gaessler,Matthew J. Higgins. Market Size and Research: Evidence from the Pharmaceutical Industry. 2021. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w28858.pdf（773KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
